Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8770943 | 0.85 | MAPT (0.45) | L3MBTL1HDAC4HDAC7HDAC5CES2 | |
| SCHEMBL22303913 | 0.84 | HDAC4 (0.47) | HDAC4HDAC7HDAC5CES2CES1 | |
| SCHEMBL8770988 | 0.84 | CES2 (0.43) | L3MBTL1HDAC4HDAC7HDAC5CES2 | |
| SCHEMBL4453208 | 0.83 | MAPT (0.44) | L3MBTL1CES2CES1MAPTALDH1A1 | |
| SCHEMBL4467344 | 0.83 | MAPT (0.44) | L3MBTL1CES2CES1MAPTALDH1A1 | |
| SCHEMBL4453212 | 0.83 | MAPT (0.44) | L3MBTL1CES2CES1MAPTALDH1A1 | |
| SCHEMBL7422382 | 0.83 | HDAC4 (0.46) | HDAC4HDAC7HDAC5CES2CES1 | |
| SCHEMBL5633627 | 0.83 | HDAC4 (0.46) | HDAC4HDAC7HDAC5CES2CES1 | |
| SCHEMBL13882102 | 0.83 | HIF1A (0.57) | L3MBTL1KDM4E | |
| Hydrochloric Acid SCHEMBL6339453 | 0.82 | HDAC4 (0.45) | HDAC4HDAC7HDAC5CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105112460-A | Method for producing (S)-4-methylbenzene methyl propionate from cells | UNIV QINGDAO SCIENCE & TECHNOLOGY | 2015-12-02 | — | — | CN | claimed |
| US-10906860-B2 | Method for synthesizing chiral beta-hydroxy acid ester compound | WENZHOU UNIVERSITY (CN) | 2021-02-02 | — | — | US | disclosed |
| US-10906860-B2 | Method for synthesizing chiral beta-hydroxy acid ester compound | WENZHOU UNIVERSITY (CN) | 2021-02-02 | — | — | US | disclosed |
| CN-109734600-B | Synthesis method of chiral beta-hydroxy acid ester compound | 温州大学 | 2020-09-15 | — | — | CN | disclosed |
| US-20200190013-A1 | METHOD FOR SYNTHESIZING CHIRAL BETA-HYDROXY ACID ESTER COMPOUND | WENZHOU UNIVERSITY (CN) | 2020-06-18 | — | — | US | disclosed |
| US-20200190013-A1 | METHOD FOR SYNTHESIZING CHIRAL BETA-HYDROXY ACID ESTER COMPOUND | WENZHOU UNIVERSITY (CN) | 2020-06-18 | — | — | US | disclosed |
| CN-109734600-A | A kind of synthetic method of chiral beta carboxylic acid ester type compound | 温州大学 | 2019-05-10 | — | — | CN | disclosed |
| CN-104603136-B | Process for preparing substituted triazolopyridines | 拜耳医药股份有限公司 | 2017-06-27 | — | — | CN | disclosed |
| CN-104114552-B | Substituted Triazolopyridine and the purposes as TTK inhibitor thereof | 拜耳知识产权有限责任公司 | 2016-12-28 | — | — | CN | disclosed |
| CN-105431435-A | Substituted triazolopyridines having activity as MPS-1 inhibitors | Bayer Pharma AG | 2016-03-23 | — | — | CN | disclosed |
| CN-105112460-A | Method for producing (S)-4-methylbenzene methyl propionate from cells | UNIV QINGDAO SCIENCE & TECHNOLOGY | 2015-12-02 | — | — | CN | disclosed |
| CN-104603136-A | Process for preparing substituted triazolopyridines | Bayer Pharma AG | 2015-05-06 | — | — | CN | disclosed |
| CN-104114552-A | Substituted triazolopyridines and their use as ttk inhibitors | BAYER IP GMBH | 2014-10-22 | — | — | CN | disclosed |
| EP-0451668-B1 | Process for the production of optically active alkyl 3-aryl-3-hydroxypropionates | CHISSO CORP (JP) | 1997-08-13 | — | — | EP | disclosed |
| US-5202457-A | Enzyme catalyzed transesterification, resolution of optical active alkyl 3-aryl-3-hydroxypropionate | CHISSO CORPORATION (JP) | 1993-04-13 | — | — | US | disclosed |
| EP-0451668-A2 | Optically active alkyl 3-aryl-3-hydroxypropionates and a method for producing thereof | CHISSO CORPORATION (JP) | 1991-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190013-A1 | METHOD FOR SYNTHESIZING CHIRAL BETA-HYDROXY ACID ESTER COMPOUND | HSD11B1, HACL2, HAAO | L3MBTL1 3381/4885HDAC4 3953/4885HDAC7 3992/4885 |
| US-10906860-B2 | Method for synthesizing chiral beta-hydroxy acid ester compound | HSD11B1, HACL2, HAAO | L3MBTL1 3381/4885HDAC4 3953/4885HDAC7 3992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.